Composition, form of production and packaging
The tablets covered with a film cover of pink color, round, biconcave; the core is from white to almost white.
trimetazidine dihydrochloride 20 mg
[PRING] Ludypress LCE - 37 mg (lactose monohydrate 94.7-98.3%, povidone - 3-4%), lactose monohydrate 37 mg, silicon dioxide colloid (aerosil) 3 mg, croscarmellose sodium 2 mg, magnesium stearate 1 mg.
The composition of the film shell: hypromellose (hydroxypropylmethylcellulose) - 3.306 mg, titanium dioxide - 0.716 mg, talc - 0.254 mg, macrogol 4000 (polyethylene glycol 4000) - 0.716 mg, dye Azorubin (E122) 0.008 mg.
10 pieces. - packings of cellular contour (1) - packs cardboard.
10 pieces. - packings cellular planimetric (2) - packs cardboard.
10 pieces. - packings cellular planimetric (3) - packs cardboard.
10 pieces. - packings cellular planimetric (6) - packs cardboard.
30 pcs. - packings of cellular contour (1) - packs cardboard.
30 pcs. - packings cellular planimetric (2) - packs cardboard.
60 pcs. - polymer cans (1) - packs of cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2011.
A drug that improves the metabolism of the myocardium and neurosensory organs under conditions of ischemia. Has antianginal, antihypoxic effect. Directly affecting the cardiomyocytes and neurons of the brain, it optimizes their metabolism and function. The cytoprotective effect is caused by an increase in the energy potential, activation of oxidative decarboxylation, and rationalization of oxygen consumption (increased aerobic glycolysis and blockade of fatty acid oxidation). Supports contractility of the myocardium, prevents the decrease in intracellular content of ATP and phosphocreatine.
In conditions of acidosis normalizes the functioning of membrane ion channels, prevents the accumulation of calcium and sodium in cardiomyocytes, normalizes the intracellular content of potassium ions. Reduces intracellular acidosis and phosphate content due to myocardial ischemia and reperfusion. Prevents the damaging effect of free radicals, preserves the integrity of cell membranes, prevents the activation of neutrophils in the ischemic zone, prolongs the duration of the electrical potential, reduces the output of CKK from cells and the severity of myocardial ischemic damage.
With angina reduces the frequency of seizures. At the same time, the consumption of nitrates is reduced, after 2 weeks of treatment, exercise tolerance is increased, blood pressure drops decrease. Against the background of the use of the drug in patients, hearing and vestibular samples improve, dizziness and tinnitus decrease.
In the vascular pathology of the eyes, the functional activity of the retina is restored when the drug is used.
After taking the drug, trimetazidine is rapidly and almost completely absorbed from the digestive tract. Bioavailability is 90%. Time to reach C max in blood plasma - 2 h. After a single dose of trimetazidine at a dose of 20 mg C max in blood plasma is about 55 ng / ml.
Binding to plasma proteins - 16%. Easily penetrates through the histohematological barriers.
T 1/2 is 4.5-5 hours. It is excreted from the body by the kidneys (about 60% - unchanged).
- IHD: prevention of angina attacks (as part of complex therapy);
- chorioretinal vascular disorders;
- dizziness of vascular origin;
- cochlear-vestibular disorders of ischemic nature (tinnitus, hearing impairment).
The drug is taken orally, with food.
The recommended dose is 40-60 mg / day (2-3 tablets) in 2-3 divided doses. The duration of the course of therapy is determined individually.
From the digestive system: rarely - gastralgia, nausea, vomiting.
Allergic reactions: itchy skin.
Other: rarely - a headache, a feeling of a strong palpitation.
- renal failure (CC <15 ml / min);
- pronounced violations of the liver function;
- the period of lactation (breastfeeding);
- children and adolescents under 18 years of age (efficacy and safety not established);
- Hypersensitivity to the components of the drug.
PREGNANCY AND LACTATION
The drug is contraindicated for use in pregnancy and lactation (breastfeeding).
APPLICATION FOR FUNCTIONS OF THE LIVER
The drug is contraindicated for use in renal failure (CC <15 ml / min).
APPLICATION FOR VIOLATIONS OF THE FUNCTION OF KIDNEYS
The drug is contraindicated for use in severe violations of liver function.
The drug is not intended for relief of angina attacks.
Against the background of drug treatment in patients with IHD, there is a significant decrease in the daily requirement for nitrates.
Impact on the ability to drive vehicles and manage mechanisms
The use of the drug does not affect the ability to engage in potentially dangerous activities that require increased attention and high speed of psychomotor reactions.
At present, no cases of an overdose of Rimecor have been reported.
The drug interaction of Rimecor is not described.
TERMS OF RELEASE FROM PHARMACY
The drug is released by prescription.
TERMS AND CONDITIONS OF STORAGE
List B. The drug should be stored in a dry, protected from light, out of reach of children at a temperature of no higher than 25 В° C. Shelf life - 3 years.